Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic

INTRODUCTION: Intravenous iloprost is currently recommended in the treatment of Raynaud's phenomenon (RP) refractory to oral therapy and of digital ulcers (DUs) related to systemic sclerosis (SSc). In real-life practice there is a huge heterogeneity about the Iloprost regimens used. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: De Lorenzis, Enrico, Natalello, Gerlando, Verardi, Lucrezia, Cerasuolo, Pier Giacomo, Gigante, Laura, D'Agostino, Maria Antonietta, Bosello, Silvia Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271454/
https://www.ncbi.nlm.nih.gov/pubmed/35835174
http://dx.doi.org/10.1016/j.mvr.2022.104404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271454/
https://www.ncbi.nlm.nih.gov/pubmed/35835174
http://dx.doi.org/10.1016/j.mvr.2022.104404

Ejemplares similares